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Abstract 
We  determined  lymphoid  enhancer-binding
factor-1 (LEF1) mRNA expression in 112 chron-
ic  lymphocytic  leukemia  (CLL)  samples  and
assessed correlations with the prognostic mark-
ers ZAP70 and CD38, Binet stages, the percent-
age of lymphocytes in the peripheral blood, and
fibromodulin  (FMOD)  transcripts.  The  mean
LEF1  relative  expression  ratios  (RER)  were
53.72 and 37.10 in ZAP70-positive and ZAP70-
negative  patients,  respectively  (P=0.004).
However, we did not observe a significant differ-
ence in LEF1 expression between CD38-positive
and CD38-negative patients. Moreover, patients
requiring treatment showed a mean LEF1 RER
of 85.61 whereas patients in recently diagnosed
Binet  A  stage  had  a  mean  of  only  22.01
(P<0.001).  We  also  found  significant  correl  -
ations of LEF1 with the percentage of lympho-
cytes and FMOD expression. Our results sug-
gest  that  high  LEF1  expression  is  associated
with poor prognosis and disease progression.
Thus, LEF1 might be involved in the process of
disease progression and possibly can serve as a
molecular parameter for risk assessment and/or
monitoring of CLL.
Introduction
Chronic lymphocytic leukemia (CLL) is the
most common leukemia in the Western world. It
is characterized by accumulation of monoclonal
CD5+ B-lymphocytes and has a highly variable
clinical  outcome.  Lymphoid  enhancer-binding
factor-1 (LEF1) is part of the LEF/TCF transcrip-
tion factor family which has been shown to play
an important role in regulating Wnt-pathway tar-
get  genes.1,2 LEF1  is  specifically  expressed  at
early  stages  of  B-cell  differentiation  and  is
essential for survival and proliferation.3
LEF1 plays a crucial role in many human
cancers.4-6 It  has  been  shown  to  be  overex-
pressed in CLL.7,8 However, the extent of over-
expression shows a high variability between
different patients. Previous research suggests
a  possible  link  between  the  degree  of  LEF1
overexpression  and  poor  prognosis  in
leukemic diseases. For example, Wang et al.
showed that LEF1 expression in highly malig-
nant acute leukemias is higher than in low-
grade chronic leukemias.4 Moreover, in acute
lymphoblastic leukemia, patients with higher
LEF1 mRNA expression caused by epigenetic
silencing  of  Wnt-suppressors  have  an  even
worse  prognosis  compared  to  patients  with
rela  tively lower LEF1 expression.9
The aim of this study was to show the prog-
nostic relevance of LEF1 expression in CLL. We
assessed correlations of LEF1 with the zeta-
associated protein 70 (ZAP70) and CD38. Both
parameters have been shown to be useful prog-
nostic markers in CLL.10,11 Moreover, we com-
pared LEF1 expression of patients in Binet C
stage  and  patients  requiring  treatment  in
Binet A/B stage with the LEF1 expression of
patients in recently diagnosed Binet A stage.
We  further  investigated  the  association
between  LEF1  and  fibromodulin  (FMOD).
FMOD is a known tumor-associated antigen in
CLL.7,8 Vallat et al. showed that fibromodulin
mRNA is highly expressed in p53-mutated CLL
cells.12 Mutations of p53 are known to be asso-
ciated with poor prognosis and therapy resist-
ance in CLL.13,14
Materials and Methods 
One  hundred  and  twelve  anonymized  CLL
patient samples left over from routine diagnos-
tic  tests  were  enriched  using  RossetteSep®
(StemCell  Technologies,  Vancouver,  BC,
Canada).  The  study  includes  patients  of  all
Binet stages, untreated patients, and patients
with a maximum of up to three prior treatment
regimens.  Fifty-four  patient  samples  were
directly processed. Fifty-eight additional sam-
ples were first frozen at -80°C in RPMI 1640
media  containing  20%  fetal  cow  serum
(Biochrome  AG,  Berlin,  Germany)  and  10%
dimethyl sulfoxide (Roth, Karlsruhe, Germany)
and later processed. Fresh and frozen samples
matched for Binet stage did not differ signifi-
cantly  in  LEF1  mRNA  expression.  B-cells  of
seven  anonymized  samples  left  over  from
healthy blood donors were used as healthy con-
trols.  Four  healthy  samples  were  enriched
using  CD19  microbeats  (Miltenyi  Biotech,
Bergisch Gladbach, Germany). The other three
healthy samples were purified using Rossette
Sep®. The healthy samples processed with the
two different methods did not differ significant-
ly in LEF1 mRNA expression.
Purification of mRNA was performed using
QIAamp RNA Blood Mini Kit (Qiagen, Hilden,
Germany). For reverse transcription to cDNA,
SuperScript® III First-Strand Synthesis System
for RT-PCR (Invitrogen, Karlsruhe, Germany)
was used. TaqMan® Probe real-time PCR was
performed using LightCycler® FastStart DNA
MasterPLUS HybProbe Kit (Roche, Grenzach-
Wyhlen, Germany). All PCR assays were per-
formed in a LightCycler® 2.0 Instrument. All
assays were started with a denaturation pro-
gram (40°C for 5 min, 95°C for 5 min) followed
by  an  amplification  and  quantification  pro-
gram with a single fluorescence measurement
repeated  45  times.  The  amplification  and
quantification program was individually opti-
mized for each assay. All assays were ended
with a cooling step to 40°C. For LEF1-PCR, the
forward primer 5’-GCCACGGACGAGATGATCC-
3’,  the  reverse  primer  5’-TGTCTGGCCAC-
CTCGTGTC-3’, and the probe 5’-6FAM-TCAAG-
GACGAGGGCGATCCTCAGAAGGAA-Dabcyl-3’
were used. The amplification and quantifica-
tion program for LEF1-PCR was 95°C for 10 s,
62°C for 15 s, and 72°C for 15 s. For FMOD-
PCR, the forward primer 5’-ATGACCCTCATTG-
GTGGTTCC-3’, the reverse primer 5’-GGAGGT-
GATCTGGTTGTTCTGGA-3’,  and  the  probe  5’-
6FAM-TACGGCTCTCCATCCCCTCCAGATCCC-
CGCGACT–TMR-3’ were used. The amplifica-
tion  and  quantification  program  for  FMOD-
PCR was 95°C for 10 s and 65°C for 20 s. FMOD
RER could be determined for only 96 samples
because  of  insufficient  sample  volume.  ABL
was used as the housekeeping gene with the
forward  primer  5’-TGGAGATAACACTCTAAG-
CATAACTAAAGGT-3’,  the  reverse  primer  5’-
GATGATGTTGCTTGGGACCCA-3’, and the probe
5’-6FAM-CCATTTTTGGTTTGGGCTTCACAC-
CATT–Dabcyl-3’. The amplification and quan-
tification program for ABL-PCR was 95°C for
10  s,  60°C  for  15  s,  and  72°C  for  15  s.  All
primers and probes were purchased from TIB
MOLBIOL (Berlin, Germany). Cycle thresholds
were  determined  by  the  second  derivative
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maximum  algorithm  using  LightCycler®
Software  3.5  (Roche,  Grenzach-Wyhlen,
Germany).  PCR-efficiency-corrected  calibra-
tor-normalized  relative  expression  ratios
(RER)  were  calculated  according  to  Roche
Applied  Science  Technical  Note  No.  LC
13/2001.15 The  healthy  B-cell  samples  were
used for calibration. In other words, the cali-
brated mean RER of healthy B-cells is 1 by def-
inition, and all other RER values are expressed
as  fold  change  compared  to  healthy  B-cells.
PCR-efficiency was calculated according to the
equation:  E=10^(–1/slope).16 The  dilution
series showed high linearity (Pearson correla-
tion coefficient r>0.99) for all RT-PCR assays.
All  sample  processing  steps  were  performed
according  to  the  respective  manufacturer’s
protocol. 
Immunophenotypic  measurements  (CD38,
ZAP70,  lymphocyte  percentage)  were  per-
formed  by  a  routine  diagnostic  laboratory
using  flow  cytometry.  The  ZAP70  assay  was
performed according to the method of Rassenti
et al.10using a monoclonal antibody specific for
ZAP70  (clone  1E7.2)  conjugated  with  Alexa
Flour  488  (Invitrogen,  Karlsruhe,  Germany).
For the CD38 assay, the monoclonal antibody
A07780  (Clone  LS198-4-3)  labeled  with  R
Phycoerythrin-Cyanin 5.1 (Beckmann Coulter,
Krefeld, Germany) was used.
Statistical  analyses  were  performed  using
GraphPad  Prism  4  (GraphPad  Software,  La
Jolla,  CA,  USA)  and  the  SPSS  17  software
(SPSS,  Chicago,  IL,  USA).  Because  the
assumptions  underlying  the  General  Linear
Model were obviously violated for our data, we
used nonparametric statistical methods such
as the Mann-Whitney U test and both Kendall’s
and Spearman’s rank correlation coefficients.
Results
Our  correlation  analyses  revealed  signifi-
cantly positive Spearman and Kendall rank cor-
relations  of  LEF1  with  the  percentage  of
ZAP70-positive CLL cells. Moreover, LEF1 was
also positively correlated with the percentage
of  lymphocytes  in  the  peripheral  blood  and
with the FMOD mRNA expression. However,
we  did  not  observe  a  positive  correlation  of
LEF1 with CD38 (Table 1).
Patients  showing  ZAP70  expression  in  at
least 20% of the CLL cells were labeled ZAP70
positive.10 Similarly,  patients  showing  CD38
expression in at least 30% of the CLL cells were
classified  as  CD38  positive.11 Comparing
ZAP70-positive  and  -negative  patients,  we
found mean LEF1 RERs of 53.72 and 37.10 in
the positive and the negative group, respect  -
ively.  This  difference  is  highly  significant
(Mann Whitney U=866.50, P=0.004) (Figure
1A). Replicating the results of our correlation
analyses, we did not observe a significant dif-
ference  in  CD38-positive  and  -negative
patients (data not shown). 
We  performed  a  LEF1  RER  median  split
dividing the patients in high and low LEF1 sub-
groups. We then compared the percentages of
lymphocytes in the peripheral blood and the
FMOD mRNA expressions in both subgroups.
We observed mean lymphocyte percentages of
88.45% and 76.28% in the high versus low LEF1
groups,  respectively  (Mann-Whitney
U=828.50,  P<0.001)  (Figure  1B).  The  mean
FMOD RER was 34.14 in the high LEF1 group
and only 4.19 in the low LEF1 group (Mann-
Whitney U=554.00, P<0.001) (Figure 2A).
The  mean  LEF1  mRNA  expression  in  our
CLL patients’ samples was 42-fold higher com-
pared  to  the  healthy  B-cell  samples  (Figure
2B).  This  difference  was  highly  significant
(Mann-Whitney U=32.00, P<0.001). 
Patients without pretreatment were split in
two groups. Group 1 consisted of Binet A stage
patients  diagnosed  less  than  one  year  ago.
Group 2 included patients in stage Binet C and
Binet  A/B  patients  requiring  treatment.  The
patients in the first group showed a mean LEF1
RER  of  22.01  whereas  those  of  the  second
group showed a mean of 85.61. This difference
was  also  highly  significant  (Mann-Whitney
U=341.50, P<0.001) (Figure 3).
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Table 1. Kendall’s ￿ and Spearman’s ￿ rank correlation coefficients between LEF1 and
ZAP70, percentage of lymphocytes in the peripheral blood (% Lymph), CD38, and
FMOD.
ZAP70 % Lymph CD38 FMOD
Kendall’s  Tau correlation 0.203 0.296 -0.100 0.302
coefficient
P 0.002 <0.001 0.119 <0.001
n 112 112 112 96
Spearman’s  Rho correlation  0.300 0.440 -0.152 0.450
coefficient
P 0.001 <0.001 0.111 <0.001
n 112 112 112 96
Figure 1. (A) Mean LEF1
RER (and standard errors)
for  ZAP70-positive  and 
-negative patients (Mann-
Whitney  U=866.50,
P=0.004).  (B)  Mean  per-
centage of lymphocytes in
the peripheral blood (and
standard  errors)  for  high
and  low  LEF1  samples
(high  =  above  LEF1  me -
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Discussion
Our finding that LEF1 is overexpressed in
CLL  cells  compared  to  healthy  B-cells  is
consist  ent with the results of previous stud-
ies.7,8 In addition, we found that LEF1 expres-
sion in CLL patients is associated with ZAP70
positivity, high percentages of lymphocytes in
the peripheral blood, and CLL disease stages
requiring treatment. This suggests a signifi-
cant role of LEF1 with respect to prognosis and
disease  progression  in  CLL.  In  contrast,  we
found no correlation between LEF1 and CD38.
CD38  has  been  shown  previously  to  be  an
IgVH-mutation-status independent prognostic
factor.11 Hence, one possible interpretation of
our  results  is  that  the  prognostic  subgroup
defined by CD38 positivity is also LEF1 inde-
pendent.  Another  possible  explanation  could
be CD38 variability during the course of CLL,11
which reduces the LEF1-CD38 correlation. We
were also able to show a strong association
between LEF1 and FMOD mRNA expression in
CLL.  Both  proteins  have  been  shown  to  be
tumor-associated antigens in CLL.7,8 Given the
fact that FMOD expression, p53 mutation, and
DNA-damage resistance have been found pre-
viously to be associated,12 the LEF1–FMOD cor-
relation  is  an  interesting  new  finding.
Eventually, it may lend additional support to
the prognostic relevance of LEF1 overexpres-
sion in CLL. 
In addition to its prognostic relevance, LEF1
is probably of great functional importance. Two
lines of evidence suggest a possible causal role
of  LEF1  in  CLL  pathogenesis.  First,  several
studies found effects of LEF1 expression on the
degree of malignancy in neoplastic diseases.
For example, LEF1 appears to mediate tumor
growth and invasion ability in androgen-inde-
pendent prostate cancer.5 Moreover, Nguyen et
al. found that LEF1 also mediates cell invasion
in  breast  cancer.6 Second,  deregulated  LEF1
expression may also be an important step in
the  development  of  neoplastic  diseases.
Consistent  with  this  idea,  Jelinek  et  al.
hypothe  sized a connection between deregulat-
ed LEF1 expression and clonal expansion of B-
cells  in  CLL.7 Other  studies  lend  additional
support to the hypothesis of LEF1 overexpres-
sion being an important oncogenic factor. For
example, LEF1 has been shown to reduce or
even eliminate transforming growth factor b-
mediated repression of the c-myc oncogene.17
Furthermore, Rivat et al. found LEF1 to take
part in transactivating the matrix metallopro-
tease matrilysin, which plays a key role in local
invasion  of  digestive  tumors.18 In  addition,
neoplastic transformation induced by LEF1 has
been  shown  both  in  vitro and  in  vivo.  For
example, Aoki et al. provided evidence for an
oncogenic effect of LEF1 in chicken fibroblasts
in vitro.19 Moreover, deregulated expression of
LEF1 in vivo has been shown to induce acute
B-lymphoblastic leukemias and acute myeloid
leukemias in mice.20
Conclusions
In a nutshell, our results suggest that high
LEF1 expression is associated with poor prog-
nosis and disease progression in CLL. Thus,
LEF1 might be involved in the process of dis-
ease progression, and possibly can serve as a
molecular  parameter  for  risk  assessment
and/or monitoring of CLL. Studies investigat-
ing LEF1 as a possible therapeutic target in
CLL are underway.
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